2023
Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.
Leapman M, Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D. Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. Journal Of Clinical Oncology 2023, 41: 333-333. DOI: 10.1200/jco.2023.41.6_suppl.333.Peer-Reviewed Original ResearchActive surveillanceProstate cancerGene expression testGenomic testingCancer riskPatient experienceGleason Grade Group 1Risk prostate cancerGrade group 1Routine clinical careProstate cancer riskGroup 2 tumorsProstate cancer managementProstate cancer aggressivenessHereditary cancer riskGermline genetic testsTissue-based testsRace/ethnicityInitial biopsyPatient knowledgeMean agePatient counselingCancer managementClinical careExpression test“It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance.
Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D, Leapman M. “It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance. Journal Of Clinical Oncology 2023, 41: 334-334. DOI: 10.1200/jco.2023.41.6_suppl.334.Peer-Reviewed Original ResearchActive surveillanceProstate cancerProstate MRIPatient experienceGleason Grade Group 1Prostate cancer active surveillanceIntermediate-risk prostate cancerRisk prostate cancerGrade group 1Group 2 tumorsMRI-ultrasound fusion biopsyMean sample ageHispanics/LatinosInitial diagnosisFusion biopsyProstate biopsyConventional content analysisPatient's perspectiveClinical careGroup 1MRI resultsMRI scansProviders' explanationsCancerPatients
2017
The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment
Viola A, Balsamo L, Neglia JP, Brouwers P, Ma X, Kadan-Lottick NS. The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment. Journal Of Pediatric Hematology/Oncology 2017, 39: 174-178. PMID: 28085741, PMCID: PMC5364064, DOI: 10.1097/mph.0000000000000761.Peer-Reviewed Original ResearchConceptsLeukemia survivorsNeurocognitive impairmentAttention-deficit/hyperactivity disorder (ADHD) outcomesPediatric acute lymphoblastic leukemia survivorsPediatric acute lymphoblastic leukemia treatmentAcute lymphoblastic leukemia survivorsAcute lymphoblastic leukemia treatmentPotential late effectsAcute lymphoblastic leukemiaMultivariate logistic regressionExecutive Function Parent FormCross-sectional studyOngoing clinical careBehavior Rating InventoryComprehensive neuropsychological assessmentElevated scoresFirst remissionClinical outcomesLymphoblastic leukemiaLate effectsClinical careRating InventoryLeukemia treatmentCognitive impairmentIndex score